I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISPOR EUROPE 2021

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Dec 3 / Roche and Genentech
Cost-effectiveness and cost-utility analyses of polatuzumab vedotin with bendamustine and rituximab vs bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma
This poster aims to assess the incremental cost-effectiveness and cost-utility ratio of polatuzumab vedotin with bendamustine and rituximab versus bendamustine and rituximab in adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant, from the Italian Health Service perspective.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 2 / Roche and Genentech
Systematic Literature Review and Network Meta-Analysis of Immunotherapy, Targeted Agents or Combination Regimens in Treatment-Naïve Unresectable or Metastatic Melanoma
This systematic literature review and network meta-analysis compared the safety and efficacy of atezolizumab plus cobimetinib plus vemurafenib (ACV) to other therapies for treatment-naive adults with unresectable or metastatic melanoma and found that ACV had the highest PFS benefit and a low rate of treatment discontinuation compared to other therapies.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 30 / Roche and Genentech
Patient and caregiver preferences for treatment attributes in Type 2 and non-ambulatory Type 3 spinal muscular atrophy: a pan-European stated preference survey
This study aimed to evaluate patient and caregiver preferences for treatment attributes in Type 2 and non-ambulatory Type 3 SMA across five European countries using an online discrete choice experiment (DCE) survey. The pooled results of this study could inform national decision making in this rare disease.